Valuation : H&R GmbH & Co KgaA

Market Cap 253M 294M 238M 217M 407M 27.99B 410M 2.82B 1.1B 14.2B 1.1B 1.08B 46.98B P/E 2026 *
5.27x
P/E 2027 * 18.4x
Enterprise Value 276M 321M 259M 237M 444M 30.52B 447M 3.07B 1.19B 15.48B 1.2B 1.18B 51.22B EV / Sales 2026 *
0.2x
EV / Sales 2027 * 0.19x
Free-Float
21.97%
Yield 2026 *
0.74%
Yield 2027 * 0.74%
08-14 H&R GmbH & Co. KGaA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
05-15 H&R GmbH & Co. KGaA Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
03-31 H&R GmbH & Co. KGaA Reports Earnings Results for the Full Year Ended December 31, 2025 CI
01-28 Kepler Cheuvreux Favors BASF and Bayer, Avoids H&R and Evonik DP
11-15 H&R GmbH & Co. KGaA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
11-14 H&R GmbH & Co. KGaA Revises Earnings Guidance for the Full Year 2025 CI
24/08/25 Nils Hansen acquired additional 7.78% stake in H&R GmbH & Co. KGaA from Srs Schmierstoff Vertrieb GmbH, ÖLfabrik Wilhelm Scholten GmbH, Wilhelm Scholten Beteiligungen GmbH and others for ?15 million. CI
15/08/25 H&R GmbH & Co. KGaA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
15/05/25 Nils Hansen proposed to acquire remaining 38.55% stake in H&R GmbH & Co. KGaA from Srs Schmierstoff Vertrieb GmbH, ÖLfabrik Wilhelm Scholten GmbH, Wilhelm Scholten Beteiligungen GmbH and others for ?73 million. CI
13/05/25 H&R GmbH & Co. KGaA Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
16/04/25 H&R GmbH & Co. KGaA announces Annual dividend, payable on May 30, 2025 CI
08/04/25 H&R GmbH & Co. KGaA Reports Earnings Results for the Full Year Ended December 31, 2024 CI
26/03/25 H&R GmbH & Co. KGaA Says Postponement Of The Publication Of The Consolidated Financial Statements And The Annual Report 2024 RE
Manager TitleAgeSince
Chief Executive Officer 61 31/12/2015
Investor Relations Contact - 31/12/2005
Director TitleAgeSince
Chairman 62 16/04/2012
Director/Board Member 71 30/04/2011
Director/Board Member 69 30/04/2011
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 291M
-0.15%+1.45%+5.83%+23.40% 125B
+9.98%+26.30%+461.34%+259.79% 55.22B
-1.71%-1.42%-18.95%-44.82% 40.19B
-2.20%+3.16%+11.25%-18.51% 36.31B
+0.94%+2.74%+42.48%+79.00% 26.47B
+1.99%+7.85%+48.10%+21.14% 20.7B
-1.58%+2.54%+9.88%+34.10% 20.57B
+2.21%-3.63%+15.49%-34.21% 20.57B
-1.43%+1.05%+45.76%+310.33% 19.31B
Average +0.80%+6.26%+69.02%+70.02% 40.53B
Weighted average by Cap. +1.19%+6.67%+80.55%+63.96%

Financials

2026 *2027 *
Net sales 1.4B 1.62B 1.31B 1.2B 2.25B 154B 2.26B 15.53B 6.04B 78.3B 6.09B 5.95B 259B 1.36B 1.58B 1.28B 1.17B 2.19B 151B 2.21B 15.16B 5.89B 76.43B 5.94B 5.81B 253B
Net income 48.09M 55.85M 45.16M 41.23M 77.39M 5.32B 77.92M 535M 208M 2.7B 210M 205M 8.93B 13.79M 16.01M 12.95M 11.82M 22.19M 1.52B 22.34M 153M 59.66M 774M 60.13M 58.81M 2.56B
Net Debt 22.87M 26.56M 21.47M 19.61M 36.8M 2.53B 37.05M 254M 98.94M 1.28B 99.72M 97.53M 4.24B 8.65M 10.05M 8.12M 7.42M 13.92M 957M 14.02M 96.27M 37.43M 485M 37.73M 36.89M 1.61B
Logo H&R GmbH & Co KgaA
H&R GmbH & Co KGaA is a Germany-based manufacturing of chemical and pharmaceutical speciality products. The Company’s two business activities are chemicals and pharmaceutical raw materials and precision plastic parts. It operates through three segments: ChemPharm Refining, ChemPharm Sales and Plastics. The ChemPharm Refining segment, which produces oils, technical and medical white oils as well as paraffins and wax products; the ChemPharm Sales segment, which produces plasticizers and wax emulsions and the Plastics segment manufacturing precision plastic parts as well as assemblies and medical consumables.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-